Archives: Agenda

Demystifying Supplier Engagement: Driving Emission Reductions through Sourcing

  • How to transition from secondary to primary supplier emissions data and bank the benefit of lower impact products in your supply chain
  • Practical approaches for prioritising suppliers, ingredients, and ingredient groups that drive meaningful impact
  • Preparing suppliers for data sharing and decarbonisation to drive action beyond reporting
  • Case studies on swaps and strategies that have actually reduced supply chain emissions

Keynote: Using AI to Predict Ingredient Demands and Formulate Next Gen Ingredient Strategies

  • The Internet: The New Source of Consumer Truth

Billions of online conversations, reviews, and recipes are reshaping how we understand consumer needs. Learn how AI Palette transforms this unstructured digital chatter into real-time, actionable insights for CPG innovation.

  • AI Transformation: From Traditional Analytics to LLMs and Agentic AI

The evolution of AI is redefining how insights are generated, moving from traditional analytics to autonomous, reasoning-driven systems that can interpret culture, context, and emotion at scale.

  • Empowering CPG Brands to Discover, Launch, and Grow with Proprietary AI

AI Palette’s patented and proprietary technology helps brands identify emerging trends, optimize product concepts, and accelerate go-to-market success – all powered by a deep understanding of consumer data and ingredient innovation.

  • The Future of Insights: Always-On, Adaptive, and Predictive

We’re entering an era where insights aren’t static reports but living, evolving systems, continuously learning from the world’s conversations to guide faster, smarter product decisions.

Interactive Session: Maximizing Site Engagement: A Sponsor’s Perspective in the Evolving Clinical Trial Landscape

·       Understanding Site Needs: Aligning sponsor strategies with site capabilities and expectations

·       Building Trust and Transparency: Fostering long-term partnerships through clear communication and support

·       Technology & Tools: Leveraging digital platforms to enhance site-sponsor collaboration

·       Metrics That Matter: Defining and tracking meaningful engagement KPIs for sustained success

PANEL DISCUSSION: Unravelling the impact of ICH E6 Revision 3: implementing new standards in good clinical practice

ICH E6 (R3) introduces significant updates to Good Clinical Practice guidelines, emphasizing risk-based quality management, patient centricity, and flexibility in trial design and execution. This panel discussion will address the impact of ICH E6 (R3) on clinical trials, comparing it to the previous ICH E6 (R2), discussing approaches to implementation, and considering varied interpretations among stakeholders.

  • Understand the key changes in ICH E6 (R3) and their implications for clinical trial conduct
  • Explore different approaches to implementing the new guidelines in diverse trial settings
  • Analyse the challenges, opportunities, and interpretations associated with ICH E6 (R3)
  • Highlight meaningful differences between ICH E6 (R2) and ICH E6 (R3) and their practical impacts

 

FIRESIDE CHAT: Leveraging Process Improvements as Strategic Assets

·       Corporate Anthropology as the basis for process innovation and optimisation

·       Viewing Process Innovation as Strategic Assets

·       Communities of Practice as vehicles for process innovation and implementing optimal ways of working

·       Process Innovation within highly regulated SOP driven environments

Navigating complexities of managing radioligand therapy oncology trials

  • Site selection considerations specific to Radiopharmaceutical Therapy (RPT) clinical trials
  • A sponsor’s perspective of the technical knowledge and expertise required to deliver RPT studies
  • Country specific RPT clinical trial requirements and regulations
  • Challenges with just-in-time supply for RPT investigational products

Has RBQM Reached Its Full Potential?

Risk-Based Quality Management (RBQM) adoption is on the rise — but for many clinical teams, the expected gains in efficiency and cost reduction have yet to materialize.

In this presentation, we’ll examine the disconnect between RBQM’s intended impact and its real-world results. We’ll explore common operational and strategic misalignments and share how TRI is helping clinical trial teams close this gap; transforming RBQM from a theoretical framework into a practical driver of performance and quality.